Smoking_cessation_agents - Articles - Page 2

Interventions to Help Patients with Depression Quit Smoking

December 12, 2013

Section editor, Glen Spielmans, PhD

...

Can Instant Messaging Enhance Treatment Outcomes?

January 1, 2012

Glen Spielmans, PhD Associate professor of psychology, Metropolitan State University, St. Paul, MN Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Whether you see your patients quarterly, monthly, or even weekly, you certainly are not with them as much as their cell phones are.

Five Treatments for Smoking Cessation Compared

February 1, 2010

Section editor, Glen Spielmans, PhD

What is the best way to help someone quit smoking? A recent trial compared the most popular over-thecounter and prescription treatments to answer this question.

Smoking Cessation: Which Options are Best?

March 1, 2008

Daniel Carlat, MD

The field of smoking cessation has been abuzz since the FDA approved Chantix (varenicline) in 2006. Pfizer’s studies showed better efficacy for Chantix than bupropion (Wellbutrin/Zyban), and the mechanism of action is fascinating. But several controversial issues have arisen to muddy the waters.

Some trouble with Chantix

January 1, 2008

John O’Reardon, MD

On November 20, 2007, the FDA issued an “early communication” warning about possible dangerous side effects of Chantix (varenicline), a new smoking cessation agent that affects brain nicotine receptors. Several cases of new-onset depression, suicidal ideation, and aggressive or erratic behavior have been reported via the Medwatch program.